ArticleFamily practice2026
Outcomes of an opioid reduction tool among patients with chronic noncancer pain in primary care.
Article in Family practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn a previous study, an opioid reduction tool was designed to reduce inappropriate opioid treatment in patients with chronic noncancer pain.
objectivesThis study aimed to assess whether the tool facilitated opioid tapering in patients with chronic noncancer pain and long-term opioid treatment in primary care. In addition, it evaluated the impact on pain-related outcome measures.
methodsIn a cohort study, 55 general practices and 30 collaborating pharmacies were recruited to implement the tool containing six reduction measures. Patients on long-term opioid treatment (>3 months) for chronic noncancer pain received a tailored taper programme from their healthcare provider and were monitored via questionnaires. The primary outcome was reduction in oral morphine equivalent daily dose over 3 months retrieved through pharmacy dispensing data. Secondary outcomes included trends in opioid use over 9 months, pain severity, pain interference, well-being, withdrawal symptoms, discontinuation rate, and nonopioid analgesic use.
resultsOf the 366 patients approached, 116 agreed to taper, of whom 27 were included in our cohort. The median oral morphine equivalent daily dose decreased significantly from 40.0 mg (interquartile range (IQR), 16.5-120.0) at baseline to 15.2 mg (IQR, 0.0-60.0) at 3 months. Opioid dose continued to decrease over 9 months, with 12 participants discontinuing completely. Pain-related outcome measures remained stable throughout the study period.
conclusionWith a significant decrease in opioid dose without negative impact on pain, this study showed promising results for an opioid reduction tool tapering long-term opioid treatment in primary care. A larger controlled trial is needed to assess the effectiveness of the tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.